Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
filingDate |
2008-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2d3e74eb083478f77b96039caf6b42a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cbf39376d2e4242e0b80838a751be61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52c8a96ba6ea671865e3f29cd57cda0a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5df8ca406809269a529af67ff90d1c5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcbaf0d8ff1a66ae5d8442e841847a70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c35dbb62410ef599ebaa864281dbb0c |
publicationDate |
2015-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20150116465-A |
titleOfInvention |
Glucagon/glp-1 receptor co-agonists |
abstract |
Disclosed is a modified glucagon peptide having enhanced potency in glucagon receptors as compared to native glucagon. Additional modifications of these glucagon peptides by forming a lactam bridge or by substitution with an amide group of a terminal carboxylic acid yield peptides that exhibit glucagon / GLP-1 receptor co-agonist activity . The solubility and stability of these highly potent glucagon analogs can be determined by pegylation, substitution of carboxy terminal amino acids, or substitution of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) Can be further improved by modification of these polypeptides by addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 28 (KRNR). |
priorityDate |
2007-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |